Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2023 03:00 ET | Source: Ethris GmbH

Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma

Phase 1 clinical trial will enroll 88 healthy volunteers in the United KingdomETH47 is a first-in-class, broadly protective antiviral candidate developed using Ethris’ proprietary platform...
November 28, 2023 03:00 ET | Source: Ethris GmbH

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received...
November 13, 2023 03:00 ET | Source: Ethris GmbH

Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure

Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissueEthris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet...
November 01, 2023 09:00 ET | Source: Ethris GmbH

Ethris Joins Alliance for mRNA Medicines as a Founding Member

MUNICH, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today it will be...
September 25, 2023 11:15 ET | Source: Ethris GmbH

DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering

Successful vaccine candidate combining DIOSynVax's computational multi-virus vaccine antigen payload technology and Ethris’ proprietary non-immunogenic messenger RNA (SNIM mRNA) and lipidoid...